Fremont, Calif.-based Zosano Pharma, Inc. announced yesterday that it will halt development of its Daily ZP-PTH treatment intended for severe osteoporosis. It plans to resume development of its Weekly ZP-PTH product. Japan’s regulatory authorities required additional studies, which would have delayed the marketing of the product by at least a year in Japan. This prompted […]

Amgen Inc said its experimental bone drug was found to be more effective than an already marketed drug in a late-stage study. Amgen’s drug, romosozumab, met the main goal of showing a significant difference over Eli Lilly & Co’s teriparatide in improving total hip bone density by the 12th month in postmenopausal women with osteoporosis. […]

Women who have pregnancies less than a year apart may have a greater risk for osteoporosis later in life than those who wait longer between babies, a study suggests. Researchers compared the reproductive histories of 239 postmenopausal women with osteoporosis to 298 similar women without thinning bones. Pregnancies no more than 12 months apart were […]

High doses of vitamin D may not help strengthen bones in postmenopausal women, a study suggests. Vitamin D helps the body use calcium, and calcium in turn helps support bone health. After a year on high-dose vitamin D supplements, women were absorbing slightly more calcium from their intestines into their blood compared to women who […]

Media reports raising safety concerns about osteoporosis drugs known as bisphosphonates may have contributed to a sharp drop in their use – even though U.S. doctors and drug regulators haven’t recommended against taking them, a study suggests. Fosamax (alendronate sodium) won U.S. marketing approval in 1995. Widespread use of the drug and others like it […]